SCHEMBL4579495

SCHEMBL4579495

Nc1ccc(-c2ccncc2)cc1NC(=O)c1cc2ccc(OCCN3CCCCC3)cc2o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.48
HDAC2 Q92769 8/20 0.46
ROCK1 Q13464 2/20 0.45
PRKACA P17612 1/20 0.45
HDAC1 Q13547 5/20 0.45
HDAC3 O15379 3/20 0.45
CYP1A2 P05177 2/20 0.44
CYP2C18 P33260 2/20 0.44
CYP2C19 P33261 2/20 0.44
KCNH2 Q12809 2/20 0.44
ROCK2 O75116 1/20 0.44
BRAF P15056 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
CCNE2 O96020 1/20 0.43
CCNE1 P24864 1/20 0.43
CDK2 P24941 1/20 0.43
GSK3B P49841 1/20 0.43
BMPR1B O00238 1/20 0.42
BMPR1A P36894 1/20 0.42
TGFBR1 P36897 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4581195 0.93 HDAC1 (0.53) HDAC2ROCK1HDAC1HDAC3CYP1A2
SCHEMBL8229221 0.86 MAOB (0.43) MAOBROCK1PRKACACYP1A2ROCK2
SCHEMBL4577533 0.85 BACE1 (0.48) HDAC2HDAC1HDAC3KCNH2
SCHEMBL4579712 0.84 HDAC1 (0.55) HDAC2HDAC1HDAC3CYP1A2
SCHEMBL4578645 0.84 HDAC1 (0.47) MAOBHDAC2HDAC1HDAC3KCNH2
SCHEMBL4579934 0.84 HDAC1 (0.51) HDAC2HDAC1HDAC3CYP1A2
SCHEMBL4581065 0.83 PAICS (0.53) HDAC2ROCK1HDAC1HDAC3CYP1A2
SCHEMBL4580187 0.81 CYP1A2 (0.48) HDAC2HDAC1HDAC3CYP1A2
SCHEMBL1063437 0.79 HDAC1 (0.54) HDAC2HDAC1HDAC3CYP1A2
SCHEMBL4581240 0.78 HDAC1 (0.55) HDAC2ROCK1HDAC1HDAC3ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007720-B1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2013-12-25 EP disclosed
US-8598168-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2013-12-03 US disclosed
EP-2007720-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2008-12-31 EP disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
WO-2007118137-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132503-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 MAOB 2499/4885HDAC2 5/4885ROCK1 874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.